3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
9 citations
,
April 2013 in “Journal of Chromatography B” A reliable method was created to measure tamsulosin in human blood.
7 citations
,
July 2003 in “Current Urology Reports” 12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
4 citations
,
January 2002 Alpha-blockers and Finasteride effectively manage BPH symptoms long-term.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
6 citations
,
July 2016 in “Gynecological Endocrinology” PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
January 2025 in “Current Trends in Pharmacy and Pharmaceutical Chemistry” New methods for measuring dutasteride are effective and reliable.
4 citations
,
March 2018 in “PloS one” Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.
2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
December 2023 in “Research and reports in urology” A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
3 citations
,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
1 citations
,
September 2023 in “Prostate International” Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
6 citations
,
January 2010 in “Neoplasma” Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
November 2012 in “The Journal of Urology” Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
September 2021 in “The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy” COVID-19 worsens urinary symptoms in men with benign prostatic hyperplasia, requiring careful treatment management.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
38 citations
,
January 2005 in “PubMed” Dutasteride effectively treats enlarged prostate with manageable side effects.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
April 2008 in “Progrès en Urologie” 7 citations
,
August 2012 in “The Journal of Urology” Women with congenital adrenal hyperplasia showed no prostatic growth.
4 citations
,
May 2013 in “Canadian Urological Association Journal” Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.
January 2017 in “Indian journal of health sciences and biomedical research KLEU” There is no link between hair loss and prostate enlargement.
4 citations
,
November 2022 in “British Journal of Cancer” Men with melanoma have a higher risk of later being diagnosed with prostate cancer.